Bristol Myers Squibb’s (BMY) “Buy” Rating Reaffirmed at Truist Financial

Bristol Myers Squibb (NYSE:BMY)‘s stock had its “buy” rating restated by Truist Financial in a report released on Friday,Benzinga reports. They currently have a $70.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $65.00. Truist Financial’s target price suggests a potential upside of 7.72% from the company’s previous close.

A number of other research firms also recently commented on BMY. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $54.00 target price on shares of Bristol Myers Squibb in a research report on Monday, July 6th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Bank of America dropped their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Guggenheim reiterated a “buy” rating and set a $75.00 price objective on shares of Bristol Myers Squibb in a research report on Friday. Nine analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $62.06.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $64.98 on Friday. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $65.56. The stock has a 50-day moving average of $57.90 and a 200 day moving average of $58.29. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a market capitalization of $132.70 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.18 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the business posted $1.46 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb will post 6.34 EPS for the current year.

Institutional Trading of Bristol Myers Squibb

Several institutional investors and hedge funds have recently modified their holdings of BMY. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb in the 4th quarter worth $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter valued at about $25,000. Physician Wealth Advisors Inc. boosted its stake in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares during the period. Bayban bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter worth about $32,000. 76.41% of the stock is currently owned by institutional investors.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Quarterly results substantially exceeded expectations. Bristol Myers reported adjusted EPS of $2.04, versus the $1.60 consensus estimate, while revenue rose 5.7% year over year to $12.97 billion, well above the $11.74 billion forecast. Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
• Positive Sentiment: Management raised its 2026 guidance. Full-year adjusted EPS is now expected at $6.75–$7.00, compared with an analyst consensus near $6.31, and revenue is projected at $49 billion–$50 billion versus expectations of approximately $47.3 billion. Bristol Myers Squibb Raises 2026 Revenue Outlook
• Positive Sentiment: Eliquis and the growth portfolio provided the key catalyst. Eliquis sales reportedly increased 21%, while newer medicines including Camzyos, Reblozyl, Breyanzi and Opdivo Qvantig helped drive growth. The growth portfolio now contributes roughly 60% of revenue and increased about 14%. Bristol-Myers Squibb Q2 2026 Earnings Call Transcript
• Positive Sentiment: Analysts and investors viewed the quarter favorably, citing strong cash flow, improved execution and an attractive valuation relative to large pharmaceutical peers. Upgrading to Buy on Positive Q2 Earnings
• Neutral Sentiment: Despite the strong report, William Blair maintained a Hold rating, indicating that the improved outlook may already reflect much of the positive news. Strong Quarter and Higher Eliquis Growth Outlook
• Negative Sentiment: Legacy portfolio revenue continues to decline because of patent expirations, while Opdivo fell and delayed readouts for Milvexian and Cobenfy introduce pipeline uncertainty.
• Negative Sentiment: Unusually heavy put-option activity—44,620 puts traded, 77% above typical volume—signals that some traders remain cautious about downside risk.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.